Generic name |
zanamivir |
---|---|
Strength | 5 mg Rotadisk |
Form |
oral inhalation |
Special Authority criteria |
Approval period |
---|---|
For the treatment and prophylaxis of influenza A and B during an outbreak among permanent residents of licensed residential care facilities (i.e., PharmaCare Plan B). |
A 5-day treatment course or up to a 28-day preventive course during the influenza season |
For the treatment of patients at high risk* of complications from influenza infection who have either:
OR
AND Initiation of treatment should be within 48 hours of symptom onset to optimize the benefits of zanamivir. Notes: *Patients at high risk of complications from influenza are defined as follows:
|
A 5-day treatment course during the influenza season |